$RXSF RATED "OUTPERFORM"/$17+ TARGET, RX Safes Releases Preliminary Research Report on Company
Analyst Highlights Company Products and Markets With an "Outperform" Rating
HENDERSON, NV -- (Marketwired) -- 12/22/15 -- Rx Safes, Inc. (OTCQB: RXSF), the developer of patented autonomous fingerprint healthcare security products announced today that it has released the company's first commissioned research report that highlights the company's products, analyzes the specific healthcare sub-markets its products are designed for, and has an outperform rating with a 2016 targeted share price of $17.41.
The research report provides a quick but thorough summary of the company and its products, provides an industry overview of the healthcare drug abuse and diversion markets, discusses recent corporate and market activity and provides an independent investment analysis provided by an industry specific analyst.
"The company wanted to start commissioning research reports in order to confirm management's business direction as well as confirm and develop shareholder opportunity. As a company, we have worked hard to develop the right technology, put that technology into the right products, are attacking the right markets with those products, and moving pro-actively in the right direction by focusing solely on the security and authorized use of controlled substances both by consumers and within professional healthcare," commented Lorraine Yarde, CEO of Rx Safes, Inc. The company is in the process of commissioning more market specific research reports that it expects to release throughout 2016.
This research report was prepared by Robert Borowski, MSc., an independent research analyst, who has provided a number of recent research reports for NASDAQ and NYSE bioscience and pharmaceutical companies such as Ohr Pharmaceutical, Calithera BioSciences and Opko Health. The report can be reviewed athttp://rxdrugsafe.com/files/Rx%20Safes%20Inc%20-%20Research%20Initiation.pdf
About Rx Safes, Inc.
Rx Safes is an emerging leader in the personal and professional healthcare drug security market. Our products incorporate proprietary patented fingerprint technology to provide drug security solutions for use in homes and healthcare facilities. Prescription drug misuse, skyrocketing insurance and pharmaceutical treatment costs and increased regulatory pressures create an unfortunate, yet necessary opportunity for Rx Safes to expand our reach and offerings in this growing market, valued at over $50 billion annually. Annual spending on healthcare technology products exceeds $34.5 billion. In addition, the market is being driven by ongoing Government support for successful drug abuse prevention initiatives, with a financial commitment of $25.4 billion in 2015 alone. For more information, please visit www.rxdrugsafe.com.
Analyst Highlights Company Products and Markets With an "Outperform" Rating
HENDERSON, NV -- (Marketwired) -- 12/22/15 -- Rx Safes, Inc. (OTCQB: RXSF), the developer of patented autonomous fingerprint healthcare security products announced today that it has released the company's first commissioned research report that highlights the company's products, analyzes the specific healthcare sub-markets its products are designed for, and has an outperform rating with a 2016 targeted share price of $17.41.
The research report provides a quick but thorough summary of the company and its products, provides an industry overview of the healthcare drug abuse and diversion markets, discusses recent corporate and market activity and provides an independent investment analysis provided by an industry specific analyst.
"The company wanted to start commissioning research reports in order to confirm management's business direction as well as confirm and develop shareholder opportunity. As a company, we have worked hard to develop the right technology, put that technology into the right products, are attacking the right markets with those products, and moving pro-actively in the right direction by focusing solely on the security and authorized use of controlled substances both by consumers and within professional healthcare," commented Lorraine Yarde, CEO of Rx Safes, Inc. The company is in the process of commissioning more market specific research reports that it expects to release throughout 2016.
This research report was prepared by Robert Borowski, MSc., an independent research analyst, who has provided a number of recent research reports for NASDAQ and NYSE bioscience and pharmaceutical companies such as Ohr Pharmaceutical, Calithera BioSciences and Opko Health. The report can be reviewed athttp://rxdrugsafe.com/files/Rx%20Safes%20Inc%20-%20Research%20Initiation.pdf
About Rx Safes, Inc.
Rx Safes is an emerging leader in the personal and professional healthcare drug security market. Our products incorporate proprietary patented fingerprint technology to provide drug security solutions for use in homes and healthcare facilities. Prescription drug misuse, skyrocketing insurance and pharmaceutical treatment costs and increased regulatory pressures create an unfortunate, yet necessary opportunity for Rx Safes to expand our reach and offerings in this growing market, valued at over $50 billion annually. Annual spending on healthcare technology products exceeds $34.5 billion. In addition, the market is being driven by ongoing Government support for successful drug abuse prevention initiatives, with a financial commitment of $25.4 billion in 2015 alone. For more information, please visit www.rxdrugsafe.com.
